Spent an interesting Wednesday afternoon, last week,  visiting exhibitors at the Bio-IT World Conference & Expo –several of whom won “Best of Show” Awards later that day.

The judges, listed below,  named winners in six categories: Data Integration & Management; Analysis & Data Computing; Genomic Data Services; Data Visualization & Exploration; Storage Infrastructure & Hardware; and the Judges’ Prize.  Attendees also voted on the People’s Choice Award, selecting products that they believed measurably improve workflow or capacity, enabling better research.

One of my favorites was Nanome, which won best in show for Data Visualization and Exploration.
Nanome uses virtual reality to improve the drug discovery process, according to its award application. The company offers applications for experimentation, collaborattion, and learning at the nano-scale– leveraging  VR hardware such as the Oculus Rift and HTC Vive to create immersive virtual workspaces allowing users to visualize, design, and simulate molecules, proteins, and more.

At  Nanom’se i BIO–IT World booth, Marketing Director Jarrell James handed me a pair of VR goggles and two joysticks (?) with which  I could explore within a molecule–by seeming to make components larger, smaller or revolve.

A more sophisticated user might be able to:

• -Import molecular structures from a local machine or an online database such as RCSB or DrugBank.
• – Manipulate molecular structures by literally grabbing, rotating, or enlarging the area of interest with their hands.
• – Apply different representations to their selection of Atoms, Residues, Chains, or Proteins such as Stick, Wire, Ball & Stick, or Van der Waals.
• – Measure distances and angles between atoms.
• – Mutate amino acids and cycle through rotamer libraries.
• – Design small molecules by building with any element from the periodic table.
• – Minimize manipulated molecules to prevent clashes and provide a local energy minimum conformation.
• – Duplicate or Split any selected area of your structure to modify or export independently.
• – Export your molecular structures to PDB.
• – Join a virtual reality session as a guest with or without virtual reality hardware.

• – Present and collaborate in the same virtual environment with colleagues to demonstrate proposals or compare before and after results.

Nanome plans next to enter the education space. The company’s VR technology wil help high school and college students , likely already proficient in gaming technology,  better understqand biologic processes, James said.

The Hyve 

I also spent some time with the folks at Hyve…whose fake robot ( that is, a “robot inhabited” by a human) did make me  curious about Hyve’s work.

RADAR-base
radar-cns.org

As described in the company’s award submission,  the company’s RADAR-base, developed in the framework of the IMI RADAR-CNS project, is an open source platform designed to securely collect, store and share readings from wearable devices and smartphone sensors to enable remote monitoring. The RADAR-base platform consists of three major categories of components:

• Data ingestion: Recognizing and registering data-sources (including smartphones and wearable devices), collecting the data via a direct Bluetooth connection or through a 3rd party API and streaming in near real time to the server (green box in the figure). Using Apache Kafka, the collected data is streamed to dedicated topics in real-time where the data is optimally schematized using Apache Avro;
• Data storage and management: Consists of two centralized storage systems behind an authorized security layer. A cold-storage based on HDFS that is scalable and fault-tolerant focusing on storing large volumes of high frequency raw-data, and a hot-storage based on MongoDB storing aggregated data to provide a near real-time overview of the raw-data. (blue box in the figure);
• Data sharing: Visualizing aggregated data in a live dashboard and exporting raw data for further analyses in various formats including AVRO, JSON and CSV (yellow box in the figure).

The platform is highly secured by a centralized management system of users and their authorities, participants, allowed devices and their specifications. RADAR-Base platform is distributed as Docker containers with associated scripts and configuration files to enable easy installation.

 In addition, I  visited Sinequa, which took the prize in the Analysis & Data Computing category. 

Sinequa ES v10
sinequa.com

The Sinequa Cognitive Search and Analytics platform handles all structured and unstructured data sources and uses Natural Language Processing (NLP), statistical analysis and Machine Learning (ML) in order to create an enriched “Logical Data Warehouse” (LDW). This LDW is optimized for performance in delivering rapid responses to users’ information needs. Users can ask questions in their native language or ask that relevant information be “pushed” to them in a timely fashion when it emerges.

More than 180 connectors ready for use “out of the box” make the process of connecting multiple data sources fast and seamless. Company and industry-specific dictionaries and ontologies can be easily integrated, putting specific knowledge “under the hood” of the Sinequa platform, making it an intelligent partner for anyone in search of relevant subject information.

Other awards, as descrbed in company literature: :

Genomic Data Services

Diploid
Moon 1.0
diploid.com/moon

Moon is the first software to autonomously diagnose rare diseases from WES/WGS data. By applying AI to the domain of rare disease diagnostics, Moon brings speed and scalability to the genome interpretation process.

The software only requires the patient’s gender, age of onset and his/her symptoms – in addition to the genetic data. Moon then goes from whole genome variant data (VCF) to pinpointing the causal variant in less than 5 minutes.

The software highlights one or a few variants that could explain the patient’s phenotype. For every variant, Moon displays an extensive list of annotations that it mined from the literature, allowing geneticists to easily verify decisions from the AI algorithms. Moon’s speed does not only save a lot of time and money, it also saves lives: Moon has already proven its utility in the NICU at Rady Children’s Hospital (San Diego): https://goo.gl/7TDrQD.

Unfortunately, about 50% of rare disease patients remain undiagnosed, even after whole genome sequencing and expert interpretation. Most hospitals don’t have the resources to keep analyzing negative cases even though new correlations between genes and disorders are published every day. Moon changes all this: as the software autonomously mines the literature and analyses samples, it can reanalyze older, negative cases in the background. Only when new information that might lead to a diagnosis becomes available, the assigned geneticist is notified. That way, hospitals can frequently reanalyze thousands of cases with minimal labor, providing a perspective to undiagnosed patients.

Storage Infrastructure & Hardware

PetaGene
PetaSuite Cloud Edition – Version 1.2
petagene.com

Launching at Bio-IT World 2018, PetaSuite Cloud Edition (CE) combines two innovations: (i) the ability for a user’s software tools and pipelines to seamlessly integrate with a wide variety of cloud platforms without modification, and (ii) significantly improved, high-performance, scalable PetaSuite genomic compression technology. 

For example, users can now directly run, without modification, their custom BWA-mem, GATK, Python, Java, shell scripts, and other POSIX-based software/pipelines streaming directly to/from AWS, Google Cloud, Azure, and private cloud storage, as though they were local filestores. PetaSuite CE supports each platform’s object encryption during transfer and at rest. User applications can connect to multiple cloud platforms, buckets and regions as desired, transparently, and on demand, in user-mode, without needing to modify their pipelines, setup mounts, or have administrator privileges.

Whether running on bare-metal, in VMs, or within Docker containers, for public, private or hybrid cloud, PetaSuite CE enables organizations to unlock the power of distributed object storage seamlessly from their POSIX-compliant tools and pipelines.

PetaSuite CE is built from the ground-up for the extremely high performance streaming and random-access workloads demanded by genomics applications. The integrated, transparent PetaGene compression has been significantly improved to deliver even faster compression and greater reductions of up to 6x of both BAM and FASTQ.GZ files, enabling large costs savings in cloud storage and data transfer times. Moreover, PetaGene compression can also preserve the MD5 checksum of the original BAM or FASTQ.GZ file and not just the internal raw SAM/FASTQ data.

The Judges’ Prize went to 

 Linguamatics and its iScite 2.0 (iscite.com) provide a Software-as-a-Service search application that puts the power of text analytics directly into scientists’ hands, according to the company writeup.

Using Linguamatics’ Award-winning Natural Language Processing
Researchers can extract and analyze relevant data to rapidly answer business-critical questions. iScite utilizes Linguamatics’ award-winning Natural Language  L(NLP) based blend of analytical methods. By understanding the semantics and structure of text, iScite handles the variety of ways people express the same information, ensuring searches are comprehensive and accurate.

Easy to use on any device
iScite’s intuitive HTML interface includes a simple search box and auto-complete suggestions. The innovative answer-routing engine lets users answer simple or complex questions using puzzle-piece building blocks – simplifying access to powerful queries that extract concepts, relationships, numerical data such as drug dosages, mutations and more.

Get answers to questions, not just documents
Data sources include Linguamatics’ cloud-hosted content. MEDLINE, Clinical Trials.gov, FDA Drug Labels, PubMed Central, and Patent Abstracts are annotated with curated terminologies for diseases, drugs, genes and organizations. Scientists can answer questions such as:

• What genes are involved in breast cancer?
• What protocol designs have been used for immuno-oncology trials?
• What are the adverse events for kinase inhibitors?

Actionable results
Results are presented in structured form, with bar chart facets for dynamic, visual results-filtering, a document viewer that highlights key terms and relationships, and relevant link-outs. Users can curate, save, and export their results.

iScite allows users across drug discovery and development to cut through the vast information landscape and discover the most valuable insights.

The People’s Choice award went to 

OnRamp BioInformatics, Inc. and itsROSALIND™ platform:  the first-ever genomics analysis platform specifically designed for life science researchers to  analyze and interpret datasets, while freeing up more time for bioinformaticians.

Named in honor of pioneering researcher Rosalind Franklin, who made a major contribution to the discovery of the double-helix structure of DNA with her famous photograph 51, OnRamp’s ROSALIND platform aims to simplify the practice of genomic data interpretation. According to the company’s writeup,  ROSALIND puts the researcher into the driver’s seat of data analysis and democratizes bioinformatics by broadly expanding access to genomic and proteomic technologies for cancer research, precision medicine and sustainable agriculture.

While many open-source tools remain the lifeline of genomic analysis, a simplified and innovative user experience for the biologist can empower them to run their own analyses, while utilizing these tools without the need for typing any command-line instructions.

ROSALIND is powered in partnership with Google Cloud and features scalable compute power and economical cloud-based storage. ROSALIND is a swarming docker-based genomic analysis solution incorporating the industry’s most trusted open-source tools and algorithms, with an angular front-end and secure RESTful API. ROSALIND is also deployable on-premise.

On Ramp technololgists believe that empowering biologists with “an intuitive and comprehensive platform” to explore their data and collaborate with colleagues and bioinformaticians, they  can help accelerate their industry and the widespread adoption of genomic technologies by dramatically lowering costs, reducing  complexity and, ultimately, focus more on what what to do with results, rather than on how to get to them.

In the words of Allison Profitt, BIO-IT World’s editor,” The awards program recognizes the best of the innovative product solutions for the life sciences industry on display at the conference,

“It’s always a treat to explore what’s new in our industry.

” The innovation on display by Bio-IT World exhibitors never disappoints, and we are excited to shine a spotlight on the best life sciences has to offer.”

Judges
“The Best of Show program relies on a panel of expert judges from academia and industry who screen eligible new products and hear presentations from a list of finalists on site. This year our judges considered 46 new products and viewed presentations on site from 18 finalists.”

The 2018 judging panel included Joe Cerro, BostonCIO; Chris Dwan, Bridgeplate; Richard Holland, New Forest Ventures; Eleanor Howe, Diamond Age Data Science; Phillips Kuhl, Cambridge Healthtech Institute; Steve Marshall, Marshall Data Solutions; Michael Miller, Genentech; Art Morales, Analgesic Solutions; Nanguneri Nirmala, Tufts University School of Medicine; Alexander Sherman, Massachusetts General Hospital; Subi Subramanian, Vertex Pharmaceuticals; Bill Van Etten, BioTeam; and Proffitt.

–Anita M. Harris
Anita Harris is a science writer based in Cambridge, MA. 
New Cambridge Observer is a publication of the Harris Commmunications Group, also in Cambridge, ma.  

Much enjoyed the current show at Lacoste--which has long been my favorite Concord, MA, Gallery. This time, owner and former ceramicist Lucy Lacoste is featuring the work of ceramicist Don Reitz– pieces from as far back as the 1960s through equally-if-not-more exciting work from 2014, just before he passed away in his 80’s.

As Lacoste explains, “Don Reitz is one of the great geniuses of contemporary ceramics and was devoted to clay, color and expression throughout his career.

“The show  encompasses three periods in the Reitz’s career– the Sara series, in which he used color to narrative stories on earthenware clay, his wood-fire period using fire and ash for expression, and his color with wood-fire and salt, which was a summation of the many elements in his life works.

‘There are also connector pieces that led from one period to the next such as the colorful plates that preceded the use of color in the Sara series and earthenware with expressive brushwork that came at the end of his life.”

My favorite pieces were those embodying both painting and sculpture. That is, ceramics in the three-dimensional form of brush strokes, incorporating  and exhibiting both color and motion. 

 
According to Lacoste, “The driving force in Reitz’ life was to be an artist and communicate through his art.  As a youth with dyslexia, he found making marks in dirt to be expressive. He took this into his ceramics throughout his career with markings on clay being his personal language. His marks, symbols and signature were always important to him whether in his salt-fire work, where the salt melted in firing to become a revealing skin; or in the ‘Sara’ period where everything was a mark or symbolic imagery done with a colorful palette; or wood-fire where the marks were revealed through the ash. The artist has always approached his work intuitively and expressively.

I Go Without Fear, 1984, earthenware, low-fire salt with engobes,

“Among the pieces in the show is a  wall plaque I Go Without Fear, 1984, earthenware, low-fire salt with engobes, 2 x 25 x 20” from his ‘Sara’ series.  Reitz’s ‘Sara Series’ was born of adversity: while he recovered from a serious car accident and his young niece from cancer, the two exchanged drawings in what amounted to a healing partnership. A childlike sensibility with color and form in abundant informs Reitz’s work from this period. This is an endearing yet powerful work showing a stick figure cautiously and optimistically moving out into the world.

Jammin’

“Jammin’, 2013 is a powerful triptych being shown for the first time from the private collection of his family.  This piece stands out for its bold, dynamic color and free calligraphic painting.  It is one of the strongest and largest of his series of triptych showing the artist at his most painterly.”
The exhibition is free and open to the public and is wheel chair accessible.
Through March 27, 2017 at the
Lacoste Gallery
25 Main Street • Concord, MA 01742
978.369.0278 • www.lacostegallery.com

–Anita M. Harris

Anita M. Harris is a writer, photographer and communications consultant based in Cambridge, MA. 
New Cambridge Observer is a publication of the Harris Communications Group, also in Cambridge, MA. 

Having made calls and canvassed for Hillary Clinton over the weekend (and joked about her seeming a bit stiff –like cardboard–in the photo to the left),  I’m saddened, confused and a bit shocked by her loss to Donald Trump. I’ll be writing more about this in days to come, but for now, thought I’d share her concession speech, which I received in an email from her campaign, so that you could read it in its entirety. I found it eloquent and inspirational.

–Anita M. Harris

Thank you.

Last night, I congratulated Donald Trump and offered to work with him on behalf of our country. I hope that he will be a successful president for all Americans.

This is not the outcome we wanted or we worked so hard for, and I’m sorry we did not win this election for the values we share and the vision we hold for our country.

But I feel pride and gratitude for this wonderful campaign that we built together –- this vast, diverse, creative, unruly, energized campaign. You represent the best of America, and being your candidate has been one of the greatest honors of my life.

I know how disappointed you feel, because I feel it too. And so do tens of millions of Americans who invested their hopes and dreams in this effort. This is painful, and it will be for a long time. But I want you to remember this: Our campaign was never about one person or even one election. It was about the country we love — and about building an America that’s hopeful, inclusive, and big-hearted.

We have seen that our nation is more deeply divided than we thought. But I still believe in America –- and I always will. And if you do, too, then we must accept this result -– and then look to the future.

Donald Trump is going to be our president. We owe him an open mind and the chance to lead.

Our constitutional democracy enshrines the peaceful transfer of power, and we don’t just respect that, we cherish it. It also enshrines other things –- the rule of law, the principle that we’re all equal in rights and dignity, and the freedom of worship and expression. We respect and cherish these things too — and we must defend them.

And let me add: Our constitutional democracy demands our participation, not just every four years, but all the time. So let’s do all we can to keep advancing the causes and values we all hold dear: making our economy work for everyone, not just those at the top; protecting our country and protecting our planet; and breaking down all the barriers that hold anyone back from achieving their dreams.

We’ve spent a year and a half bringing together millions of people from every corner of our country to say with one voice that we believe that the American Dream is big enough for everyone — for people of all races and religions, for men and women, for immigrants, for LGBT people, and people with disabilities.

Our responsibility as citizens is to keep doing our part to build that better, stronger, fairer America we seek. And I know you will.

I am so grateful to stand with all of you.

I want to thank Tim Kaine and Anne Holton for being our partners on this journey. It gives me great hope and comfort to know that Tim will remain on the front-lines of our democracy, representing Virginia in the Senate.

To Barack and Michelle Obama: Our country owes you an enormous debt of gratitude for your graceful, determined leadership, and so do I.

To Bill, Chelsea, Marc, Charlotte, Aidan, our brothers, and our entire family, my love for you means more than I can ever express.

You crisscrossed this country on my behalf and lifted me up when I needed it most –- even four-month old Aidan traveling with his mom.

I will always be grateful to the creative, talented, dedicated men and women at our headquarters in Brooklyn and across our country who poured their hearts into this campaign. For you veterans, this was a campaign after a campaign — for some of you, this was your first campaign ever. I want each of you to know that you were the best campaign anyone has had.

To all the volunteers, community leaders, activists, and union organizers who knocked on doors, talked to neighbors, posted on Facebook – even in secret or in private: Thank you.

To everyone who sent in contributions as small as $5 and kept us going, thank you.

And to all the young people in particular, I want you to hear this. I’ve spent my entire adult life fighting for what I believe in. I’ve had successes and I’ve had setbacks -– sometimes really painful ones. Many of you are at the beginning of your careers. You will have successes and setbacks, too.

This loss hurts. But please, please never stop believing that fighting for what’s right is worth it. It’s always worth it. And we need you keep up these fights now and for the rest of your lives.

To all the women, and especially the young women, who put their faith in this campaign and in me, I want you to know that nothing has made me prouder than to be your champion.

I know that we still have not shattered that highest glass ceiling. But some day someone will -– hopefully sooner than we might think right now.

And to all the little girls watching right now, never doubt that you are valuable and powerful and deserving of every chance and opportunity in the world.

Finally, I am grateful to our country for all it has given me.

I count my blessings every day that I am an American. And I still believe, as deeply as I ever have, that if we stand together and work together, with respect for our differences, strength in our convictions, and love for this nation -– our best days are still ahead of us.

You know I believe we are stronger together and will go forward together. And you should never be sorry that you fought for that.

Scripture tells us: “Let us not grow weary in doing good, for in due season, we shall reap, if we do not lose heart.”

My friends, let us have faith in each other. Let us not grow weary. Let us not lose heart. For there are more seasons to come and there is more work to do.

I am incredibly honored and grateful to have had this chance to represent all of you in this consequential election. May God bless you and god bless the United States of America.

Hillary

Anita M. Harris, a writer and communications consultant, is the author of Broken Patterns, Professional Women and the Quest for a New Feminine Identity. Broken Patterns is about women of the baby-boom generation in relation to their mothers and grandmothers. It presents a spiral theory of change, which, Harris believes, goes far in explaining the current election results.

New Cambridge Observer is a publication of the Harris Communications Group, based in Cambridge, MA.

(Cambridge, MA) The Community Dispute Settlement Center (CDSC) will be honoring three community peacemakers for their work in the courts, at-risk young adults, and high school students. The public is invited to join us in celebrating with community mediators, educators, lawyers and community leaders at the Venture Café in the Cambridge Innovation Center on Wednesday, October 14th. Tickets to the event need to be purchased in advance on CDSC’s web site: www.communitydispute.org

Cambridge Dispute Resolution Center

At the event CDSC will be recognizing the work of: Hon. John Cratsley (ret.), a leader in alternative dispute resolution standards and implementation in the Massachusetts courts; Jon Feinman, the founder of InnerCity Weightlifting of Cambridge, an innovative program that uses fitness training as a tool to reduce violence and promote professional, personal and academic achievement among urban youth; and The Cambridge Rindge and Latin School Mediation Team, a resource for the school’s students to develop skills and resolve interpersonal issues fully and peacefully.
CDSC, established in 1979, is a private non-profit mediation and training center, dedicated to providing an alternative and affordable forum for resolving conflict. CDSC promotes better ways to understand and deal with conflict through skilled teams of volunteer mediators, training programs in mediation and conflict management, and broad community outreach. It also collaborates with local schools to create peer mediation programs and skill-building workshops that help youth deal with conflict.
For more information about CDSC or to arrange a training workshop for a school, youth group or organization, please call 617-876-5376, emailcdscinfo@communitydispute.org, or visit the CDSC’s website at: http://www.communitydispute.org.

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning PR and marketing firm based at the Cambridge Innovation Center in Cambridge, MA.

Butterly-from Ariana Pharma Website

Our Cambridge Innovation Center colleague Ariana Pharma reports that it has joined the WIN consortium as an official technology partner. Congrats! Here’s the release. 

Paris, France, and Cambridge, Massachusetts USA, 29 October 2014 – Ariana Pharma, developer of innovative clinical data analysis and diagnostic solutions for the healthcare sector, today announced it has joined the WIN Consortium as an official technology partner. The Consortium (Worldwide Innovative Networking in personalized cancer medicine) is a global collaboration of 40 leading organizations whose aim is to develop more effective cancer diagnostics and therapeutics, shorten clinical trial timelines and reduce the overall cost of cancer care.

The new WIN/Ariana partnership is expected to accelerate the translation of personalized medicine discoveries into widely available new standards of care for all cancer patients, leading to significantly improved clinical outcomes and a higher quality of life for cancer patients.

As a technology partner of the WIN Consortium, Ariana will have early access to the latest research, key opinion leaders, leading academic groups and personalized medicine clinical trials. Ariana uses OncoKEM^®, a proprietary clinical decision support platform for personalized medicine, to transform big data into better therapeutic decisions for cancer patients.

Ariana Pharma Founder and Chief Executive Officer Dr. Mohammad Afshar said: “We are delighted to be an official technology partner of the WIN Consortium where we can continue to leverage our expertise in patient stratification, multi-marker diagnostic optimization and data mining to transform complex clinical data into actionable information. Our expanded access to the leading global stakeholders in personalized medicine will allow us to test new hypotheses, to enhance interaction to yield valuable feedback and thus accelerate the development process and commercialisation of these critical new services for the global cancer community.”

“We are delighted to welcome Ariana Pharma in our consortium. Ariana Pharma provides outstanding computational skills enabling the translation of academic projects into commercial tools to support the therapeutic decision for cancer patients,” said Dr. John Mendelsohn, Chairman of the WIN Consortium.

WIN is recognized for pioneering the evolution of next-generation clinical trials, which test personalized treatment selection strategies rather than single drugs. These strategies are driven by algorithms that match targeted therapies or combination therapies to individual tumor biological profiles based on diagnostic analysis of genomic data and other information.

In 2013 the WIN Consortium chose Ariana Pharma to develop and globally commercialize ground-breaking decision support software in WIN’s WINTHER trial, the first state of the art clinical trial in personalized cancer medicine to help clinicians choose the best therapies for cancer patients. Ariana retains exclusive global rights to commercialize software and algorithms validated by the WINTHER clinical trial through Ariana’s OncoKEM^® platform.

About Ariana Pharma

Ariana Pharma develops innovative clinical data analysis and diagnostic testing solutions to help the healthcare sector better adapt patient treatments to individual biological characteristics. Ariana Pharma’s KEM^® technology enables personalization of therapies, improves the efficacy and safety of patient treatment, reduces risks and drug development costs, and accelerates time to market. KEM^® is the only FDA tested technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for personalized medicine. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company opened a subsidiary in the United States in 2012.For more information, please visit www.arianapharma.com

About the WIN Consortium

Founded in 2010, WIN is an initiative from the Institut Gustave Roussy (France) and University of Texas MD Anderson cancer center (USA). WIN is unique structurally in that it brings together organizations from academia, business and not-for-profits to focus on translating the latest advances in personalized cancer medicine into the standard of care. WIN is built on the recognition that all stakeholders in personalized cancer therapy must collaborate and share information, in order to effectively bring the latest innovations in personalized cancer care to the patient. WIN is a non-profit organization formed by 40 renowned members: Academic cancer centres (25 centres in 16 countries), companies (Blue Cross Blue Shield, Agilent Technologies, GE Healthcare, Oracle Health Services, Foundation Medicine, Millennium Takeda, AstraZeneca and Pfizer), non-profit organizations such as EORTC, Fondation ARC and Sage Bionetworks. WIN organizes an annual symposium in Paris dedicated to personalized medicine. For further information, please visit www.winconsortium.org  and www.winsymposium.org.

–Anita M Harris
New Cambridge Observer is a publication of the Harris Communications Group, an award-winning pr and marketing firm based in Cambridge, MA. {Ariana is not our client]. AMH.

Image for Life Science Innovation Day 2014

On Tuesday, June 3, the Massachusetts Life Science Center (MLSC) will host  its 7th Mass Life Sciences Innovation  Day at the Harvard Club on Commonwealth Avenue, in Boston. Billed on its Website as “the biggest day for life sciences startups and innovation in the Commonwealth of Massachusetts,” Mass Life Science Innovation Day is  “a high-energy, hands-on event” at which scientific leaders and business experts mingle with scientists, post-docs, professors, entrepreneurs, innovators, and venture capitalists.  

“This is one of the best opportunities to hear about trends affecting life sciences start-ups and to learn about new technologies that are ready for commercialization, ”  according to Abigail Barrow, Director of the Massachusetts Technology Transfer Center and the conference chair,  

A central question to be addressed at the event involves creativity, according to Barrow. That is, can researchers still be creative with the organizational and financial demands that are placed on research environments?  Do corporations and academics still have the courage to allow their teams to be really creative? If you want to do interesting and exciting science can you still get the funding? How does business and finance leadership view creativity?

“Our speakers and panelists will discuss the current battle to create innovation friendly environments and its impact on entrepreneurs and young researchers finding jobs.”

The morning session will feature a keynote address by Mark Levin, who will speak about how Third Rock, the  venture capital firm he founded,  invests in new companies.

 Brock Reeve, Director of the Harvard Stem Cell Institute, will be the luncheon speaker.
Morning and afternoon breakout sessions featuring more than 40 speakers will cover scientific topics such as indication selection, experiment design and managing research programs as well as entrepreneurial topics including  “how to join the venture capital club,”  how to pitch your new idea, and “where to find money to fund your start-up.”

Some 30 early-stage companies and major research institutions will present posters and compete for prizes to be awarded at the close of the day by State Senator Karen Spilka.  The award-winners will be chosen by 20 Life Science CEOS and biotech leaders who will also attend a closing reception. The reception will include an Innovators Marketplace offering resources needed to commercialize an invention.

 More information on the program and registration is available on  the MLSC website at  –http://www.mattcenter.org/malsi-day-2014/home.html .

Here’s a link to the agenda and a complete list of speakers.
Conference fees range from $60 for students  to $550 for two marketplace exhibitors.

Massachusetts Life Sciences Innovation Day was  developed by the Massachusetts Life Sciences Start-up Initiative (MALSI)–a platform organization that brings together all major public and private entities in the State that are committed to building the next generation of Massachusetts companies. MALSI’s mission is to ensure that Massachusetts maintains its lead as the #1 region in the world to start, nurture and grow life sciences companies.  MALSI partners include: Massachusetts Technology Transfer Center, MassBio, Mass Medical Angels, TiE Boston, and several major universities and research hospitals.

–Anita M. Harris
Anita Harris is an author, photographer  and communications consultant based ib Cambridge, MA. 

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning PR and marketing firm based in Cambridge, MA.